SciELO - Scientific Electronic Library Online

 
vol.21 número2Treatment outcomes in conventional high-grade osteosarcoma in children and adolescents: An analysis of survival of a cohort treated without methotrexateThe effect of aging on the burden of cancer in Colombia: projections for the top five frequently occurring cancers in Colombia by Department and gender for 2020 and 2050 índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Artigo

Indicadores

Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google

Compartilhar


Revista Colombiana de Cancerología

versão impressa ISSN 0123-9015

Resumo

ANGULO, Javier et al. Survival of Castration-Resistant Prostate Cancer in Clinical Practice and the Role of Treatment. rev.colomb.cancerol. [online]. 2017, vol.21, n.2, pp.95-103. ISSN 0123-9015.  http://dx.doi.org/10.1016/j.rccan.2017.03.002.

Purpose:

To assess, in a clinical practice context, the survival advantages of patients with castration-resistant prostate cancer (CRPC) actively treated with several treatments that include abiraterone acetate (AA) and prednisone, with or without docetaxel.

Material and Methods:

An analysis was performed on patient survival with CRPC, and was compared to a group treated with AA and prednisone (n = 33), with a historical control treated exclusively with anti-androgen withdrawal and palliative measures (n = 31). In the population actively treated, variables predictive of prognosis were analysed, as well as an evaluation of the overall response to AA and radiographic progression-free survival.

Results:

Cancer-specific survival at 2 years was 79% for patients actively treated and 17.2% for control group (P<.0001). Five (38.5%) of 13 patients treated with AA post-docetaxel received second-line chemotherapy after AA (4 cabazitaxel, 1 vinorelbine), and one (7.7%) enzalutamide.

Three (15%) of 20 patients treated with AA without chemotherapy received enzalutamide and

1(5%) docetaxel. The younger patients (<65yrs; P=.02) without metastases at diagnosis (P=.04) had better prognoses. Patients with higher PSA levels (>45 ng/ml; P=.09) and a Gleason pattern 5 in the biopsy had less favourable outcomes. There was a 75.8% over response to AA (80% preand 69.2%post-chemotherapy; P=.1), and 69.2%post-chemotherapy; P=.1), and 52.4% were radiographic progression-free at 1 year of treatment (47.9% pre- and 49.8% post-chemotherapy; P=.3).

Conclusion:

Treatment of CRPC patients extends survival expectations in a clinical practice setting and prognostic predictors can be identified in these patients.

Palavras-chave : Castration-resistant prostate cancer; Treatment; Abiraterone Acetate; Systemic chemotherapy; Survival; Prognostic factors.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )